Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Pharma Research International, Inc
A clinical research provider that conducts clinical research for pharmaceutical and biotechnological companies as well as government sponsored trials. We also facilitate training programs for clinical research practitioners and site preparation for studies.
We also aim to help clinical research facilities and professionals conduct clinical trials following GCP/ICH. By doing so we believe will be beneficial to pharmaceutical companies as it would allow for clinical trials to run smoother and more efficiently. It will also help subjects get quality service during the clinical studies.
Donec sodales a quam in imperdiet. Aliquam massa libero, malesuada nec interdum sit amet, gravida quis nibh. Praesent facilisis tristique egestas. Curabitur vitae metus vitae libero iaculis suscipit. Nullam non velit metus. Curabitur at euismod felis. Aenean viverra sem sit amet ante bibendum, sit amet vehicula eros dapibus.
Emilio Munoz
PresidentPharmagest
Nutrition and Weight Loss
Rare Disease
Your innovative solution
Remote surveillance system that improves the medical monitoring of patients treated by Peritoneal Dialysis and monitoring of the health of haemodialysis patients in self-dialysis structures.
Slow the progression to terminal Chronic Renal Insufficiency (CRI). Decrease the cardiovascular morbi-mortality.Helps management and evaluation .Better control over patient at lower cost Estimated annual savings of $10,000 per patient. Assistance with billing; more effective thanks to the control panels. Less hospitalisation.
E health / Care / Medical Devices
Selected as part of the Second e-Health call for projects under the French Government / expert systems / results
Erwan SALQUE
E-Healt DirectorPoliwogg
We build financial products so you can participate in the healthcare and life science economy. Companies, investors, consumers and entrepreneurs will have access to financial products to create and/or manage their financial exposure to healthcare and the life science sector.
Poliwogg's management team has extensive experience in finance, healthcare, foundations, government and investing. It combines that expertise with a passion for increasing and broadening investment in healthcare, the largest sector of the American economy.
PORSOLT
CNS-Neurology
Dermatology
Gastroenterology / Hepatology
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Psychiatry/Psychology
Rheumatology
Your innovative solution
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission.
Porsolt provides physiopathological models in multiples species, customized procedures, and tailored solutions, (including in vitro assays and drug formulation analysis and bioanalytical services), for psychiatric and neurological disorders, pain, cardiac and vascular diseases, metabolic and eating disorders, and dermatology.
Pharmaceutical companies / Biotechs / Fondations / Academia
Science-based / GLP compliance / tailored solutions / flexibility
Guillaume FROGET
Chief Executive Officer & PresidentPPRS Research
Rare Disease
Your innovative solution
Somno-Art is an ambulatory monitoring device allowing the scoring of the user's sleep internal structure with results equivalent to those obtained from the complex polysomnography (PSG). Based on the recordings of two basic and easy-to-measure physiological variables, heart rate and body movements, our in-house software produces a full description of the sleep architecture
Around 20% of the overall population suffers from chronic sleep disorders resulting in tens of billion dollars of productivity losses with serious repercussions on the overall health of people (blood pressure, obesity, chronic fatigue...). Somno-Art will allow easier and faster sleep diagnostics compared to traditional sleep monitoring devices.
Research market / Sleep labs market / Medical market
Medical results / Automatic scoring / Ambulatory / Easy-to-use
Mr Fabrice AUROUSSEAU
CEOPrecision for Medicine
At Precision for Medicine, we specialize in accelerating the development, approval and launch of complex or first-in-class medical technologies. We work regularly with medical device, diagnostics and life sciences companies as well as with investors in this space. We have expert teams in each of regulatory affairs, biostatistics and analytics, clinical trial services, commercial strategy and market access/reimbursement. Our experts work within and across these verticals to develop the latest techniques for product success.
Core services include:
To-Market Strategy, a collaborative effort to manage risk and maximize opportunity at each stage of product development
Due Diligence and Opportunity Assessments, to inform potential investments or new areas of product development
Regulatory Strategy and Support, including U.S. FDA, E.U. and global regulatory stratgies, negotitations and submissions
Evidence Development Strategy, including advanced non-clinical and clinical trial designs, statistical analysis plans, and literature-based approaches
Clinical Trial Services, from study start through conclusion and reporting
KOL Recruitment and management of key clinical advisors (CABs, SABs, KOLs, expert panels and reports, study investigators, etc.)
Market Access Services, including payer communications, reimbursement strategy, and health economics
Personalized Medicine Strategies, including responder analyses, companion diagnostics and biomarker identification
Digital Medicine Strategy, including software-based products and accessory apps
Business Strategy, including business model ideation, market research, due diligence and fundraising support
Premier Heart, LLC
oronary Artery Disease (CAD) is the leading cause of death worldwide, accounting for over 7 Million deaths annually — more than any other disease category.
Premier Heart's Multifunction Cardiogram is the only non-invasive online diagnostic testing tool designed to assist physicians in quickly and accurately detecting heart diseases, including CAD ischemia.
When compared to traditional methods MCG has consistently been able to more accurately detect ischemia at earlier stages, enabling physicians to intervene and save lives.
The results from MCG have been validated in double-blind clinical studies where our system has demonstrated accuracy comparable to coronary angiography (90% overall sensitivity, 85% specificity).
This level of accuracy results from advanced techniques in signal processing and systems analysis combined with our unmatched clinical database which allows MCG to provide quantitative, evidence-based results to assist in reaching a diagnosis.
We invite you to review our clinical trial results, user endorsements and technical data. If you want to learn more about using MCG in your practice or would like more information about our technology please feel free to contact us.
Dr Joseph Shen
ManagerProception Medical
Proception in-licenses Medtech IP, improves the IP, develops the products, gains regulatory approval, gains clinical experience and then out-licenses the product to a large medical device company using a unique out-licensing model.
Mr Mike McGuinness
COOProtecsom
ProtecSom designs smart respiratory drug delivery devices to improve pulmonary drug distribution and patients life.
Industry sectors Medtech Therapeutics Area Pediatrics/NeonatologyPulmonary/Respiratory Diseases
Your innovative solution
Optim'Hal provides real-time information on the drug dose inhaled from a metered dose inhaler with a spacer device. It sends this information to any computer, smartphone or tablet and also converts it as light and sound signals to encourage drug taking among toddlers.
Compliance is a major problem with asthma sufferers. Thanks to incentive provided to patients, children and parents, Optim'Hal improves compliance. The inhaled dose and speed of the inspiratory flow are critical to the reliability of the inhaled treatment. Thanks to information about these settings, Optim'Hal' makes the treatment more reliable.
Asthma and COPD sufferers. /Any inhaled treatment. /Research centers about aerosoltherapy.
Better compliance, thanks to incentive signals or applications depending on the age / Better surveillance, thanks to true data on patient compliance available for caregivers / Improving pulmonary drug distribution thanks to information on inspiratory flow